Micellar formulation provides potent and tolerable TLR7 agonist treatment for anti-cancer immunotherapy.

Christensen E, Stavnsbjerg C, Münter R, Bak M, Panina S, Halldórsdóttir HR, Petersen M, Kempen P, Jensen M, Kjaer A, Henriksen JR, Hansen AE, Jensen S, Andresen TL

Open source

DOI: 10.1093/jimmun/vkaf043
Published: 2025 Jul 1
Container: Journal of immunology (Baltimore, Md. : 1950)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/jimmun/vkaf043,
  title = {Micellar formulation provides potent and tolerable TLR7 agonist treatment for anti-cancer immunotherapy.},
  author = {Christensen E and Stavnsbjerg C and Münter R and Bak M and Panina S and Halldórsdóttir HR and Petersen M and Kempen P and Jensen M and Kjaer A and Henriksen JR and Hansen AE and Jensen S and Andresen TL},
  year = {2025},
  journal = {Journal of immunology (Baltimore, Md. : 1950)},
  doi = {10.1093/jimmun/vkaf043},
  url = {https://doi.org/10.1093/jimmun/vkaf043}
}

RIS

TY  - JOUR
TI  - Micellar formulation provides potent and tolerable TLR7 agonist treatment for anti-cancer immunotherapy.
AU  - Christensen E
AU  - Stavnsbjerg C
AU  - Münter R
AU  - Bak M
AU  - Panina S
AU  - Halldórsdóttir HR
AU  - Petersen M
AU  - Kempen P
AU  - Jensen M
AU  - Kjaer A
AU  - Henriksen JR
AU  - Hansen AE
AU  - Jensen S
AU  - Andresen TL
PY  - 2025
JO  - Journal of immunology (Baltimore, Md. : 1950)
DO  - 10.1093/jimmun/vkaf043
UR  - https://doi.org/10.1093/jimmun/vkaf043
ER  -

APA

E, C., C, S., R, M., M, B., S, P., HR, H., M, P., P, K., M, J., A, K., JR, H., AE, H., S, J., & TL, A. (2025). Micellar formulation provides potent and tolerable TLR7 agonist treatment for anti-cancer immunotherapy.. Journal of immunology (Baltimore, Md. : 1950). https://doi.org/10.1093/jimmun/vkaf043

Source records

pubmed · retrieved 2026-11-10T19:01:41.482Z